Shopping Cart
Remove All
Your shopping cart is currently empty
Brolucizumab
😃Good
Catalog No. T80593Cas No. 1531589-13-5
Alias RTH258, ESBA 1008, DLX1008
Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Brolucizumab
Brolucizumab
😃Good
Catalog No. T80593Alias RTH258, ESBA 1008, DLX1008Cas No. 1531589-13-5
Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $813 | - | In Stock | |
| 5 mg | $2,270 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:≥95% (SDS-PAGE); 99.67% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD). |
| In vitro | Brolucizumab (2683 nM) inhibits VEGFR1 phosphorylation in VEGF-A112-induced U87MG human glioma cells and VEGFR2 phosphorylation in ZHE-483-2 GMECs. [1] |
| In vivo | Brolucizumab (15 mg/kg, intravenous injection, five days a week) was used to treat mSLK-KSHV xenografts and the tumor growth in vivo was observed. Results: Brolucizumab slowed the growth of mSLK-KSHV xenograft tumors. [2] |
| Synonyms | RTH258, ESBA 1008, DLX1008 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | VEGFA |
| Molecular Weight | ~150 kDa |
| Cas No. | 1531589-13-5 |
| Isotype | scFv-kappa-heavy |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Brolucizumab | purchase Brolucizumab | Brolucizumab cost | order Brolucizumab | Brolucizumab in vivo | Brolucizumab in vitro | Brolucizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.